Advanced Oncotherapy #AVO – Final Results statement plus CEO and Chairmans report

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces audited results for the year ended 31 December 2017, another year of significant technological development and installation of the Company’s first LIGHT system. Key highlights: ·     Successful integration of three of the four key LIGHT system structures significantly reducing technical […]

Advanced Oncotherapy #AVO – Update on Financing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has received £10 million from Yantai Cipu, through its affiliated entity Liquid Harmony, in relation to the balance of payments due under the Distribution Agreement announced on 7 December 2017. This completes the £30 million investment from […]

Advanced Oncotherapy #AVO – Notice of General Meeting

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a circular convening the Company’s General Meeting to be held at the Royal Institute of British Architects, 66 Portland Place, London W1B 1AD at 10:00am on Tuesday, 23 January 2018, in relation to the transactions announced on 7 December 2017 has […]

Nicolas Serandour, CEO of Advanced Oncotherapy #AVO discusses Yantai deal & £37m equity investment with BRR Media

Nicolas Serandour, CEO of Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, announces that they have signed an exclusive distribution agreement with Yantai CIPU Medical Technology to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. At the same time, the Company has secured £20.9 […]

Advanced Oncotherapy #AVO – Exclusive distribution agreement for China and other geographies & new equity investments for a total consideration of £37m

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an exclusive distribution agreement with Yantai CIPU Medical Technology Co. Ltd. to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. Under the agreement, Yantai CIPU will make a payment of £16.5 […]